Google takes $100M plunge into telehealth

Google Cloud is injecting $100 million into a supplier of telehealth platforms, partly to build out AI systems for helping hospitals remotely handle patient inquiries, intake and triage.

The Silicon Valley behemoth and Boston-based Amwell jointly announced their multipronged plans Aug. 24.

Google Cloud says the $100M investment will be contingent on the closing of Amwell’s upcoming IPO, which also was announced this week.

Among related aims the pair will pursue are translation services via natural language processing, collaboration tools to facilitate staff communications and patient engagement, and data analytics methodologies to monitor patients in homecare settings.

The partnership will allow Amwell (formerly American Well) to refine and scale its telehealth offerings for providers, insurers and patients in current and prospective Amwell markets, according to the joint announcement.

In addition, the partnership will seek to simplify healthcare processes for underserved populations while also helping healthcare workers serve seniors and patients with chronic conditions “in a dramatically new way without compromising on care quality or user trust.”

 

 

Related Telehealth Content:

Patient demand for telemedicine remains strong

Telehealth claims surged in 2020

AMA pushes for equity in telehealth

Walmart acquires telehealth provider MeMD

Telehealth demand starts to soften

More than 200 advocates call on governors to retain telehealth flexibilities

HHS awards $55 million to expand virtual healthcare access

Telehealth visits have declined since the onset of COVID-19

Find more telemedicine stories

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.